Case report: ALK D1225N missense mutation in lung adenocarcinoma responds to tyrosine kinase inhibitors
ALK gene missense mutations are conventionally considered non-driver mutations without pathological significance, and therefore, there is a lack of effective target drugs against them. The standard treatment option for patients with ALK missense mutations is chemotherapy with or without antiangiogen...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Book |
| Published: |
Frontiers Media S.A.,
2023-07-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000 am a22000003u 4500 | ||
|---|---|---|---|
| 001 | doaj_b0a7c3a93acd484ea9d20b10a8ca701d | ||
| 042 | |a dc | ||
| 100 | 1 | 0 | |a Jianxin Chen |e author |
| 700 | 1 | 0 | |a Junhui Wang |e author |
| 245 | 0 | 0 | |a Case report: ALK D1225N missense mutation in lung adenocarcinoma responds to tyrosine kinase inhibitors |
| 260 | |b Frontiers Media S.A., |c 2023-07-01T00:00:00Z. | ||
| 500 | |a 1663-9812 | ||
| 500 | |a 10.3389/fphar.2023.1190447 | ||
| 520 | |a ALK gene missense mutations are conventionally considered non-driver mutations without pathological significance, and therefore, there is a lack of effective target drugs against them. The standard treatment option for patients with ALK missense mutations is chemotherapy with or without antiangiogenic agents, which usually results in unsatisfactory outcomes. Herein, we present the case of a patient with metastatic lung adenocarcinoma harboring the only missense mutation in ALK D1225N responding to two ALK-tyrosine kinase inhibitors (TKIs), namely, crizotinib and ensartinib. Our case highlights that non-small cell lung cancer (NSCLC) patients harboring the D1225N mutation may benefit from ALK-TKIs, and therefore, ALK-TKIs should be considered candidates for further line treatment. | ||
| 546 | |a EN | ||
| 690 | |a ALK gene | ||
| 690 | |a missense mutations | ||
| 690 | |a tyrosine kinase inhibitors | ||
| 690 | |a lung adenocarcinoma | ||
| 690 | |a non-small-cell lung cancer | ||
| 690 | |a Therapeutics. Pharmacology | ||
| 690 | |a RM1-950 | ||
| 655 | 7 | |a article |2 local | |
| 786 | 0 | |n Frontiers in Pharmacology, Vol 14 (2023) | |
| 787 | 0 | |n https://www.frontiersin.org/articles/10.3389/fphar.2023.1190447/full | |
| 787 | 0 | |n https://doaj.org/toc/1663-9812 | |
| 856 | 4 | 1 | |u https://doaj.org/article/b0a7c3a93acd484ea9d20b10a8ca701d |z Connect to this object online. |